6-[4-(2-trifluoromethylbenzyl)piperazin-1-yl]pyridazine-3-carboxylic acid (3-methylbutyl)amide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-[4-(2-trifluoromethylbenzyl)piperazin-1-yl]pyridazine-3-carboxylic acid (3-methylbutyl)amide
• 英文别名: N-(3-methylbutyl)-6-[4-[[2-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]pyridazine-3-carboxamide
• 化学式: C₂₂H₂₈F₃N₅O
• 分子量: 435.492
• InChiKey: GATFEPZZBAGMCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  异戊胺 在 氯化亚砜 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二甲基甲酰胺 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 2.5h， 生成 6-[4-(2-trifluoromethylbenzyl)piperazin-1-yl]pyridazine-3-carboxylic acid (3-methylbutyl)amide
  参考文献：
  名称：

  Piperazine derivatives and their use as therapeutic agents

  摘要：

  公开号：

  EP2316827B1

文献信息

• Pyridazine derivatives and their use as therapeutic agents
  申请人：Chakka Nagasree

  公开号：US20060009459A1

  公开（公告）日：2006-01-12

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (Ia): where x, y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明涉及一种治疗哺乳动物（优选为人类）SCD介导的疾病或病症的方法，其中所述方法包括向需要治疗的哺乳动物中给予式(Ia)的化合物，其中x、y、W、V、R2、R3、R4、R5、R6、R6a、R7、R7a、R8、R8a、R9和R9a如本文所定义。此外，本发明还涉及含有式(I)的化合物的制药组合物。
• PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS
  申请人：Billich Andreas

  公开号：US20110021530A1

  公开（公告）日：2011-01-27

  Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human, including administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein, and compositions including a compound of formula (I).

  治疗哺乳动物，尤其是人类SCD介导的皮肤疾病或症状的方法，包括向需要该治疗的哺乳动物施用式(I)的化合物，其中x，y，W，V，R2，R3，R4，R5，R6，R6a，R7，R7a，R8，R8a，R9和R9a在此定义，并包括含有式(I)化合物的组合物。
• Piperazine derivatives and their use as therapeutic agents
  申请人：Xenon Pharmaceuticals Inc.

  公开号：EP2316827B1

  公开（公告）日：2016-01-27
• Discovery of Potent, Selective, Orally Bioavailable Stearoyl-CoA Desaturase 1 Inhibitors
  作者：Gang Liu、John K. Lynch、Jennifer Freeman、Bo Liu、Zhili Xin、Hongyu Zhao、Michael D. Serby、Philip R. Kym、Tom S. Suhar、Harriet T. Smith、Ning Cao、Ruojing Yang、Rich S. Janis、Joel A. Krauser、Steven P. Cepa、David W. A. Beno、Hing L. Sham、Christine A. Collins、Teresa K. Surowy、Heidi S. Camp

  DOI：10.1021/jm070219p

  日期：2007.6.1

  Stearoyl-CoA desaturase 1 (SCD1) catalyzes the committed step in the biosynthesis of monounsaturated fatty acids from saturated, long-chain fatty acids. Studies with SCD1 knockout mice have established that these animals are lean and protected from leptin deficiency-induced and diet-induced obesity, with greater whole body insulin sensitivity than wild-type animals. In this work, we have discovered a series of potent, selective, orally bioavailable SCD1 inhibitors based on a known pyridazine carboxamide template. The representative lead inhibitor 28c also demonstrates excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells.